Delivery Order SPE2DB22D3501-SPE2DB25FXC90
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 80 milligrams, for the treatment of Crohn's disease, ulcerative colitis, and other health conditions. This non-competitive delivery order, valued at $4,531.80, was executed on August 7, 2025, with an ultimate completion date of August 8, 2025. The contract utilizes firm fixed pricing and represents a pediatric or specialized pharmaceutical supply requirement being...
- The Defense Logistics Agency awarded a delivery order valued at $1,147.29 to AmerisourceBergen Drug Corp for the supply of HUMIRA (CF) Pen for Crohn's disease and ulcerative colitis treatment at an 80-milligram dose strength. This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, was competitively awarded without set-aside designation. The product will be delivered to the Conshohocken, Pennsylvania location, which serves as...
- The Defense Logistics Agency awarded a delivery order valued at $1,132.95 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen for Crohn's disease and ulcerative colitis treatment at 80 milligrams. The award, made on July 21, 2025, with an ultimate completion date of July 22, 2025, utilizes firm fixed pricing with no set-aside designation. This delivery order falls under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion...
- The Defense Logistics Agency awarded a $4,531.80 delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The place of...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of HUMIRA Pen 40mg/4mL (2 pens) with a ceiling value of $26,615.29. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 15, 2025. HUMIRA...
- The Defense Logistics Agency awarded a delivery order valued at $9,063.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA (adalimumab) 40 mg/0.4 mL prefilled pens. The contract was competitively awarded without set-aside provisions and carries a firm fixed price structure with an ultimate completion date of August 5, 2025. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single...
- The Defense Logistics Agency has awarded a delivery order valued at $1,510.60 to AmerisourceBergen Drug Corp for the supply of HUMIRA Pen 40 mg/0.8 mL units. This competitively awarded, firm fixed price contract was executed on August 4, 2025, with an ultimate completion date of August 5, 2025. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication for treating autoimmune conditions including rheumatoid arthritis,...
- The Defense Logistics Agency awarded a delivery order valued at $5,485.29 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen injections, 40 mg/0.4 mL. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 31, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a widely used biologic medication prescribed for autoimmune conditions including...
- The Defense Logistics Agency awarded a delivery order valued at $3,214.62 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mls, a injectable medication used to treat autoimmune conditions. The contract, issued on July 30, 2025, is a firm fixed price delivery order with an ultimate completion date of July 31, 2025. The award carries no set-aside designation and represents a competitively awarded transaction. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a $2,265.90 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 28, 2025, with an ultimate completion date of August 29, 2025. This non-set-aside contract represents a pharmaceutical supply delivery under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery location is...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXC90Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) pen formulations in 80 mg doses for the treatment of Crohn's disease and ulcerative colitis, with a ceiling value of $1,132.95. The contract, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, utilized firm fixed-price pricing and was not set-aside. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance and is a major pharmaceutical distributor specializing in federal medical procurement for military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. This prime contract vehicle supports comprehensive global pharmaceutical supply to military healthcare programs worldwide, enabling the company to deliver a broad range of specialty medications, brand-name and generic drugs, and medical supplies. As a competitively awarded contract, this delivery order reflects AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements and aligns with DLA's strategy to maintain flexible, reliable supply chains for critical medications across therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 9/2/25 |